A novel tumour marker RCAS1 in a case of extramammary Paget's disease
A novel tumour marker RCAS1 in a case of extramammary Paget's disease
复制标题
一种新型肿瘤标志物 RCAS1 在乳房外佩吉特病中的应用
DOI：
10.1046/j.1365-2230.2003.01251.x
复制
发表时间：
2003
影响因子：
4.1
通讯作者：
H. Nawata
中科院分区：
文献类型：
--
作者：
M. Enjoji;K. Noguchi;H. Watanabe;Y. Yoshida;K. Kotoh;M. Nakashima;T. Watanabe;M. Nakamuta;H. Nawata
一名66岁男性，其乳房外佩吉特病原发性皮肤病变4年前已手术切除，因肝转移住院。 进行肝动脉灌注化疗，肿瘤明显缩小。即使在治疗前，一些常见肿瘤标志物的血清水平也没有升高。我们测量了一种新的肿瘤相关抗原RCAS 1的血清水平，因为它在肿瘤细胞中表达。患者的血清RCAS 1水平在治疗前升高（22.0 U/mL），在治疗期间（10.5 U/mL）和治疗后（5.0 U/mL）下降。 因此，血清RCAS 1水平可能作为监测佩吉特病治疗效果的潜在生物标志物是有价值的。
A 66‐year‐old male, whose primary skin lesion in extramammary Paget's disease had been surgically resected 4 years previously, was hospitalized with liver metastases. Hepatic arterial infusion chemotherapy was carried out and the tumours clearly reduced in size. Serum levels of some common tumour markers were not elevated, even prior to therapy. We measured serum levels of a novel tumour‐associated antigen, RCAS1, because its expression was detected in the tumour cells. The patient's serum RCAS1 level was elevated (22.0 U/mL) before therapy and fell during (10.5 U/mL) and after (5.0 U/mL) therapy. Therefore, serum RCAS1 levels may be valuable as a potential biomarker for monitoring therapeutic efficacy against Paget's disease.
K. Sonoda、M. Nakashima、T. Watanabe 等人：“一种在人类子宫癌和卵巢癌上表达的新型肿瘤相关抗原”癌症。
DOI：
--
发表时间：
--
期刊：
影响因子：
--
作者：
通讯作者：
--